美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SPDR S&P Pharmaceuticals ETF

66.94

-0.8100-1.20%

盤後：66.94-0.00220.00%19:30 EDT

成交量：54.93萬

成交額：3,677.35萬

市值：5.72億

市盈率：25.93

高：67.74

開：67.74

低：66.78

收：67.75

52周最高：74.35

52周最低：45.82

股本：855.03萬

流通股本：855.03萬

量比：3.11

換手率：6.42%

股息：0.34

股息率：0.51%

每股收益(TTM):2.58

每股收益(LYR):-0.1280

淨資產收益率：42.40%

總資產收益率：0.26%

市淨率：1.34

市盈率(LYR):-522.90

資料載入中...

總覽公司新聞資訊公告

專利到期潮撞上研發斷檔，生物類似藥「空窗」逼近！美國醫療體系恐少省1890億美元

專利到期潮撞上研發斷檔，生物類似藥「空窗」逼近！美國醫療體系恐少省1890億美元

百時美施貴寶就安進擬推出的Opdivo生物類似藥提起訴訟

對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內

每日经济新闻

松江奇蹟：一家中國藥企的「體系化出海」豪賭｜未來企業調研行

华夏时报网

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

全球118款生物藥即將失去專利或獨佔權，生物類似藥的「潑天富貴」來了？

山德士擬投資3億美元在斯洛文尼亞建設生物類似藥原料藥工廠

山德士擬投資3億美元在斯洛文尼亞建設生物類似藥原料藥工廠

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

台裕製藥提交針對HER2陽性乳腺癌的抗體藥物偶聯物生物類似藥TSY-110的臨床試驗申請。

【券商聚焦】招銀國際維持藥明生物（02269）「買入」評級指生物類似藥將成新驅動力

復宏漢霖盤中漲近8% 近期聯手山德士出海至多10款生物類似藥

復星醫藥子公司攜生物類似藥出海牽手全球仿製藥龍頭，鎖定四成銷售分成

每日经济新闻

復宏漢霖與山德士達成戰略合作

復宏漢霖擬向山德士授權至多10款生物類似藥，國產生物藥國際化再進一步｜醫藥早參

每日经济新闻

復宏漢霖攜手Sandoz佈局生物類似藥首批3款產品落地

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/XPH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"XPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","market":"US","secType":"STK","nameCN":"SPDR S&P Pharmaceuticals ETF","latestPrice":66.94,"timestamp":1789761600000,"preClose":67.75,"halted":0,"volume":549335,"hourTrading":{"tag":"盘后","latestPrice":66.9378,"preClose":66.94,"latestTime":"19:30 EDT","volume":332439,"amount":22252753.7564,"timestamp":1789774205794,"change":-0.0022,"changeRate":-0.000033,"amplitude":0.000033},"delay":0,"changeRate":-0.011955719557195606,"floatShares":8550270,"shares":8550270,"eps":2.581957,"marketStatus":"休市中","change":-0.81,"latestTime":"09-18 16:00:00 EDT","open":67.74,"high":67.74,"low":66.78,"amount":36773468.209649995,"amplitude":0.01417,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":2.581957,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":67.75,"sharesOutstanding":5750270,"nav":67.859224,"aum":580214690.85,"dividendRate":0.005079,"bidAskSpread":0.001861,"preHourTrading":{"tag":"盘前","latestPrice":67.75,"preClose":67.75,"latestTime":"07:37 EDT","volume":1,"amount":67.75,"timestamp":1789731462581,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":66.9378,"preClose":66.94,"latestTime":"19:30 EDT","volume":332439,"amount":22252753.7564,"timestamp":1789774205794,"change":-0.0022,"changeRate":-0.000033,"amplitude":0.000033},"volumeRatio":3.107928132550368,"impliedVol":0.0618,"impliedVolPercentile":0.0398},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","floatShares":8550270,"roa":"0.26%","roe":"42.40%","lyrEps":-0.128016,"volumeRatio":3.107928132550368,"shares":8550270,"dividePrice":0.34,"high":67.74,"amplitude":0.01417,"preClose":67.75,"low":66.78,"week52Low":45.82,"pbRate":"1.34","psRate":"261.25","week52High":74.345,"institutionHeld":0,"latestPrice":66.94,"eps":2.581957,"divideRate":0.005079,"volume":549335,"delay":0,"ttmEps":2.581957,"open":67.74,"prevYearClose":56.01,"prevWeekClose":67.51,"prevMonthClose":70.62,"prevQuarterClose":66.27,"fiveDayClose":67.51,"twentyDayClose":72.29,"sixtyDayClose":64.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XPH\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"XPH","amount":0.04164,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-23","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-23"},{"date":"2026-06-22","symbol":"XPH","amount":0.059045,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2026-03-23","symbol":"XPH","amount":0.060954,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-25","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-25"},{"date":"2025-12-22","symbol":"XPH","amount":0.113024,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XPH","amount":0.102634,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XPH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.091273,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.026956,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.085023,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.07227,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-21","value":0.019429,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XPH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668916276","title":"專利到期潮撞上研發斷檔，生物類似藥「空窗」逼近！美國醫療體系恐少省1890億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668916276","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668916276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 09:45","pubTimestamp":1789695928,"startTime":"0","endTime":"0","summary":"美国因此面临着一个巨大的“生物类似药空窗”，这可能导致1890亿美元的医疗成本节约空间流失。据AAM统计，去年仿制药与生物类似药合计为美国节约医疗开支4960亿美元，较2024年增加300亿美元;其中仿制药贡献了95%的节约额。AAM表示，生物类似药的研发主要瞄准市场潜力大、专利即将到期的生物药。那些专利到期前年销售额超10亿美元的原研药，对应的生物类似药竞争尤为激烈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2272731782.SGD","PPH","LU2322448791.USD","BK4585","LU1992135399.USD","LU1992135472.HKD","LU2473716301.USD","LU2322448957.HKD","IE00B5TLWC47.USD","LU2272731600.USD","159891","BK4588","XPH","IBB","LU2272731865.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668162209","title":"專利到期潮撞上研發斷檔，生物類似藥「空窗」逼近！美國醫療體系恐少省1890億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668162209","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668162209?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 09:45","pubTimestamp":1789695928,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731600.USD","PPH","XPH","BK4588","BK4585","LU2322448957.HKD","LU1992135399.USD","IE00B5TLWC47.USD","LU2473716301.USD","LU2272731782.SGD","LU2322448791.USD","IBB","LU2272731865.HKD","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667267605","title":"百時美施貴寶就安進擬推出的Opdivo生物類似藥提起訴訟","url":"https://stock-news.laohu8.com/highlight/detail?id=2667267605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667267605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 10:15","pubTimestamp":1789524901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2468319806.SGD","LU1868836757.USD","BBH","LU1670711123.USD","XPH","PBE","LU1983299246.USD","LU0225284248.USD","TBXU","LU1868837300.USD","LU2322448957.HKD","LU0320765992.SGD","LU2272731600.USD","LU1992135399.USD","LU1023059063.AUD","LU1261432733.SGD","BMY","LU2473716301.USD","IBBQ","IBB","BK4139","AMGN","LU0289739699.SGD","LU1236620834.HKD","FTXH","BK4534","LU2272731865.HKD","LU1868836591.USD","LU0868494617.USD","LU1883839398.USD","PJP","LU1989771016.USD","BK4585","LU0109394709.USD","IE0009355771.USD","BK4566","LU1236620750.USD","LU0114720955.EUR","BK4533","IE00B4R5TH58.HKD","LU0225771236.USD","LU0061475181.USD","BK4559","BIB","LU2125154778.USD","LU0058720904.USD","PPH","BK4588","IE00BSNM7G36.USD","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667660668","title":"對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660668","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667660668?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 01:03","pubTimestamp":1789405401,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药延续高增长态势。国家药监局数据显示，2026年1~6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。《每日经济新闻》记者（以下简称每经记者）注意到，从上市公司半年报来看，首付款作为部分企业BD（商务拓展）收入的一部分，让利润表短暂“翻红”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873800338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873800338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","LNGR","XPH","LU1992135472.HKD","LU2322448957.HKD","BK1161","LU2272731600.USD","LU1992135399.USD","LU2473716301.USD","LU2272731782.SGD","IBBQ","IBB","LU2272731865.HKD","BK4585","06978","MEDX","IE00B5TLWC47.USD","LU2322448791.USD","BK1574","PPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666503466","title":"松江奇蹟：一家中國藥企的「體系化出海」豪賭 ｜ 未來企業調研行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666503466","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666503466?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 12:14","pubTimestamp":1789186482,"startTime":"0","endTime":"0","summary":"编者按：9月的一天，《华夏时报》未来企业竞争力调研团队来到位于上海松江的复宏汉霖全球生产基地——中国生物制药版图上，一处正在悄悄改写规则的所在。这家中国生物药企拒绝只卖“青苗”，而是试图用生物类似药的现金流，搭建从临床、报批到商业化的全球闭环。但真正的考验在于：创新药管线能否在专利悬崖窗口期兑现为第二增长曲线。上海松江，文俊路618弄。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609123872706781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609123872706781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BCG","XPH","IE00B5TLWC47.USD","LU2322448957.HKD","BK4588","LU2272731782.SGD","LU1992135472.HKD","IBB","BK4585","LU2473716301.USD","PPH","BK4135","LU2272731865.HKD","LU2272731600.USD","LU2322448791.USD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SBIO","FBT","BIB","AZNH","GNOM","WDNA","BK4588","IBB","RSPH","BK4585","PSCH","HELX","IBRN","BBP","MRNY","PBE","FTXH","IYH","IDNA","BIOY","LU1992135472.HKD","LU2272731865.HKD","PJP","MRNX","LU2272731600.USD","IEIH","LU2322448791.USD","LU2322448957.HKD","XPH","LU2272731782.SGD","XBIX","IE00B5TLWC47.USD","BBH","CANC","SYNB","LU1992135399.USD","TMED","BME","IEHS","LFSC","PBPH","PPH","RXL","LU2473716301.USD","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666235705","title":"復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666235705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666235705?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:44","pubTimestamp":1789119840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的药品注册申请获国家药品监督管理局受理。此次申报适应症为其参照药安加维于中国境内已获批上市的所有适应症。据悉，HLX14为公司自主研发的地舒单抗生物类似药。截至公告日期，HLX14已分别于美国、欧盟、英国、加拿大获批上市。截至2026年8月，公司现阶段针对HLX14的累计研发投入约为3.52亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","XPH","BK0175","LU2322448957.HKD","BK0196","BK1515","BK4588","LU1992135399.USD","600196","LU2322448791.USD","BK0188","IBB","BK1191","LU1992135472.HKD","PPH","LU2272731865.HKD","BK0028","BK0012","LU2272731782.SGD","BK0187","BK0239","02196","IE00B5TLWC47.USD","BK0183","BK0096","BK0060","BK4585","LU2473716301.USD","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356195?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2322448791.USD","BK4588","BK1574","HK0000306701.USD","HK0000320264.USD","IBBQ","LU1992135472.HKD","MEDX","BK4585","LU2473716301.USD","LU2272731865.HKD","PPH","06978","LU2272731782.SGD","IBB","XPH","HK0000306685.HKD","BK1161","IE00B5TLWC47.USD","LU2272731600.USD","HK0000320223.HKD","LU2322448957.HKD","02696","159992","HK0000165453.HKD","LU1992135399.USD","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533226","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533226","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:54","pubTimestamp":1788958467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731782.SGD","IBBQ","LU1992135472.HKD","IBB","LU2322448957.HKD","XPH","LNGR","LU2272731600.USD","LU2272731865.HKD","PPH","BK4585","LU1992135399.USD","LU2322448791.USD","IE00B5TLWC47.USD","BK4588","LU2473716301.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580032","title":"全球118款生物藥即將失去專利或獨佔權，生物類似藥的「潑天富貴」來了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580032","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580032?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954152,"startTime":"0","endTime":"0","summary":"中国市场中生物类似药面临集采降价的潜在压力，而市场的增长潜力在哪？9月8日，在复宏汉霖开放日活动上，波士顿咨询公司（BCG）合伙人杜菁表示，全球正迎来生物类似药发展的重大窗口期，重磅原研药集中进入专利悬崖，叠加欧美政策持续利好，预计2035年全球生物类似药市场规模将突破2400亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093869495082.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093869495082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XPH","LU2272731865.HKD","LU2322448957.HKD","LU2322448791.USD","LU2473716301.USD","LU2272731782.SGD","PPH","BK4588","BK4585","LU1992135399.USD","LU2272731600.USD","IBB","LU1992135472.HKD","159839","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665425173","title":"山德士擬投資3億美元在斯洛文尼亞建設生物類似藥原料藥工廠","url":"https://stock-news.laohu8.com/highlight/detail?id=2665425173","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665425173?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:24","pubTimestamp":1788845041,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2272731865.HKD","LU2322448791.USD","IBB","LU2272731782.SGD","BK4585","LU2272731600.USD","PPH","BK4588","IE00B5TLWC47.USD","LU2473716301.USD","LU1992135472.HKD","LU2322448957.HKD","XPH","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342830","title":"山德士擬投資3億美元在斯洛文尼亞建設生物類似藥原料藥工廠","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342830","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342830?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:20","pubTimestamp":1788844815,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B5TLWC47.USD","LU1992135399.USD","LU2322448791.USD","LU1992135472.HKD","LU2272731600.USD","PPH","BK4588","LU2272731782.SGD","LU2272731865.HKD","LU2473716301.USD","LU2322448957.HKD","BK4585","XPH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PSCH","PBE","IE0009355771.USD","PPH","HELX","LFSC","RXL","SYNB","BK4007","LU0211331839.USD","BBP","IEIH","MRNX","AZNH","FTXH","LU2473716301.USD","FBT","MEDX","TMED","BME","BIOY","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","PBPH","LU2272731600.USD","BK4585","IYH","SBIO","BIB","XPH","BK4588","IE0002141913.USD","LU2322448957.HKD","MEDI","RSPH","XBIX","MRNY","GNOM","IEHS","IDNA","IBB","IE00BFTCPJ56.SGD","PJP","WDNA","NVS","IE00B4R5TH58.HKD","CANC","IBRN","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060177","title":"台裕製藥提交針對HER2陽性乳腺癌的抗體藥物偶聯物生物類似藥TSY-110的臨床試驗申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060177","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 20:03","pubTimestamp":1787918605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","PPH","LU2272731865.HKD","IBB","LU2322448791.USD","XPH","BK4585","LU2272731782.SGD","MDTX","LU1992135399.USD","LU2272731600.USD","LU2322448957.HKD","IBBQ","BMED","LU2473716301.USD","IBBJ","LU1992135472.HKD","PSYK","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778813","title":"【券商聚焦】招銀國際維持藥明生物（02269）「買入」評級 指生物類似藥將成新驅動力","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778813","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778813?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 13:20","pubTimestamp":1787808047,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，药明生物 2026年上半年业绩强劲，收入同比增长18.4%至人民币118亿元，经调整净利润增38.4%至33亿元。毛利率升至46.2%，总积压订单达251亿美元。生物类似药将成M端新支柱。公司已有17个生物类似药项目，未来三年已承诺20个项目，80%客户来自全球前十企业。维持“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989738","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","PPH","KCE","XPH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660747701","title":"復宏漢霖盤中漲近8% 近期聯手山德士出海至多10款生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2660747701","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660747701?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 10:56","pubTimestamp":1787194560,"startTime":"0","endTime":"0","summary":"模拟交易客户端复宏汉霖盘中涨近8%，截至发稿，股价上涨6.87%，现报70.05港元，成交额1646.58万港元。基于上述首批约定，山德士将向复宏汉霖支付首付款、相关里程碑付款及不可退还的选择权费共计至高3.22亿美元；2026年，复宏汉霖预计可达成的开票金额总计不超过1.005亿美元。值得一提的是，海外市场已成为复宏汉霖业绩增长的重要组成部分。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-20/doc-ininxqxw2099208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306685.HKD","HK0000306701.USD","LU1992135472.HKD","LU2272731865.HKD","LU2473716301.USD","XPH","IBB","HK0000320264.USD","LU2272731782.SGD","LU2272731600.USD","IE00B5TLWC47.USD","BK4588","BK1161","02696","HK0000165453.HKD","PPH","LU1992135399.USD","LU2322448791.USD","LU2322448957.HKD","HK0000320223.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660866704","title":"復星醫藥子公司攜生物類似藥出海 牽手全球仿製藥龍頭，鎖定四成銷售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2660866704","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660866704?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:26","pubTimestamp":1786958770,"startTime":"0","endTime":"0","summary":"8月17日，复星医药（SH600196，股价24.01元，市值588.9亿元）公告披露，其控股子公司复宏汉霖与全球生物类似药龙头SandozAG于8月16日签订《合作框架协议》。双方约定，可就复宏汉霖至多10款单克隆抗体（mAb）和/或抗体偶联药物（ADC）生物类似药，开展海外区域的注册、商业化、开发、生产等许可合作，并已就首批3款产品达成具体商业条款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843260444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843260444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","BK0188","LU2322448791.USD","LU2272731865.HKD","LU2272731600.USD","BK1515","LU1992135472.HKD","LU2272731782.SGD","BK4585","PPH","BK0196","BK0012","BK1191","BK1593","BK0060","BK4588","BK0239","LU2322448957.HKD","BK0183","LU1992135399.USD","600196","BK0175","BK0187","XPH","02196","IE00B5TLWC47.USD","BK0028","LU2473716301.USD","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660857514","title":"復宏漢霖與山德士達成戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2660857514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660857514?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:05","pubTimestamp":1786957508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2272731782.SGD","IBB","XPH","LU1992135472.HKD","PPH","LU2322448957.HKD","BK4588","LU1992135399.USD","BK4585","LU2473716301.USD","LU2272731865.HKD","LU2322448791.USD","LU2272731600.USD","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660106203","title":"復宏漢霖擬向山德士授權至多10款生物類似藥，國產生物藥國際化再進一步｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2660106203","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660106203?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 09:33","pubTimestamp":1786930438,"startTime":"0","endTime":"0","summary":"过去一周（截至8月14日收盘），创新药板块震荡上行。打包医药全产业链的医药ETF（512120）上涨0.2%，聚焦A股创新药的生物医药ETF（159508）上涨1.77%，聚焦港股创新药的港股通生物科技ETF（159102）上涨0.12%。相关个股中，康龙化成上涨8.48%、药明康德上涨2.85%、恒瑞医药下跌3.66%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842706171.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842706171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","PPH","LU2272731865.HKD","IBB","LU2322448791.USD","BK4585","XPH","HK0000320223.HKD","LU2272731782.SGD","02696","HK0000165453.HKD","09939","LU1992135399.USD","HK0000306685.HKD","LU2272731600.USD","LU2322448957.HKD","HK0000306701.USD","159938","BK1574","LU2473716301.USD","BK1161","BK1515","159839","HK0000320264.USD","LU1992135472.HKD","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660110620","title":"復宏漢霖攜手Sandoz佈局生物類似藥 首批3款產品落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2660110620","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660110620?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 09:22","pubTimestamp":1786929720,"startTime":"0","endTime":"0","summary":"8月17日，复宏汉霖（02696）发布公告，公司于2026年8月16日与SandozAG达成战略合作框架协议，预计2026年可实现的开票金额总计不超过1.01亿元美元。此次合作开发最多10款单抗和/或ADC生物类似药相关产品，后续针对各个产品另行签订附属协议确定具体合作条款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842662937.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842662937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","IBB","BK4585","02696","IE00B5TLWC47.USD","LU2322448791.USD","HK0000320223.HKD","LU2473716301.USD","HK0000306701.USD","BK1161","LU2322448957.HKD","LU2272731782.SGD","PPH","HK0000306685.HKD","XPH","HK0000320264.USD","LU2272731865.HKD","LU2272731600.USD","BK4588","LU1992135472.HKD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}